Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

ClinicalTrials.gov Identifier

NCT03602079

Institution Name

The University of Texas MD Anderson Cancer Center

Full Institution Address

Houston Texas 77030 United States

Additional Institutions

Florida Cancer Specialists & Research Institute Sarasota, Florida, United States, 34232 Beth Israel Deaconess Medical Center Cancer Center Boston, Massachusetts, United States, 02215 Karmanos Cancer Institute Detroit, Michigan, United States, 48201 Clinical Research Alliance, Inc. Lake Success, New York, United States, 11042 Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 Providence Cancer Institute Portland, Oregon, United States, 97213 Mary Crowley Cancer Research Centers - Medical City Dallas, Texas, United States, 75230 South Texas Accelerated Research Therapeutics, LLC (START) San Antonio, Texas, United States, 78229 Virginia Cancer Specialist Fairfax, Virginia, United States, 22031

Principal Investigator

Jordi Rodon Ahnert, M.D., PhD

Principal Investigator Phone

(713) 563-1930

Principal Investigator Email

yjiang@mdanderson.org

Additional Principal Investigators

Virginia Cancer Specialist Contact: Alexander Spira, MD, PhD,FACP 703-280-5390 Alexander.Spira@usoncology.com

Study Coordinator

Yunfang (Jenny) Jiang

Study Coordinator Phone

(713) 794-1751

Study Coordinator Email

yjiang@mdanderson.org

Additional Study Coordinators

Florida Cancer Specialists & Research Institute Contact: Donna L Jones, BSN, RN, OCN, 941-377-9993 Beth Israel Deaconess Medical Center Cancer Center Contact: Cassandra Cruz 617-975-7411 clcruz@bidmc.harvard.edu Karmanos Cancer Institute Contact: Valerie Davis 313-576-9370 davisv@karmanos.org Clinical Research Alliance, Inc. Contact: Colleen Kats ckats@researchcra.com Stephenson Cancer Center Contact: Dana Suters 405-271-8778 SCC-Clinical-Trials-Office@ouhsc.edu Providence Cancer Institute Contact: Christina Lopez 503-215-2614 Christina.Lopez4@providence.org Mary Crowley Cancer Research Centers - Medical City Contact: Amy Jordan 972-566-3000 referral@marycrowley.org South Texas Accelerated Research Therapeutics, LLC (START) Contact: Isabel Jimenez, RN, MSN 210-593-5265 isabel.jimenez@startsa.com

Study Overview

Study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies. Patients must have documented HER2 expression or amplification. The patient must have exhausted available standard therapies. Cycles will continue until disease progression or unacceptable toxicity.

Enrollment Information

102

Study Start Date

20180716

Study End Date

20200110

Financial Assistance Available

No

---